These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line. Perrin GQ; Fishbein L; Thomson SA; Thomas SL; Stephens K; Garbern JY; DeVries GH; Yachnis AT; Wallace MR; Muir D J Neurosci Res; 2007 May; 85(6):1347-57. PubMed ID: 17335073 [TBL] [Abstract][Full Text] [Related]
5. Genetic and clinical considerations in six cases with neurofibromatosis type 1. Buteică E; Stoicescu I; Burada F; Stănoiu B Rom J Morphol Embryol; 2007; 48(3):243-8. PubMed ID: 17914490 [TBL] [Abstract][Full Text] [Related]
6. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation. Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122 [TBL] [Abstract][Full Text] [Related]
11. Neurocristopathy resembling neurofibromatosis type 1 in an NGF-SV40 transgenic line. Mazarakis ND; Yannoutsos N; el-Jabbour JN; Hatton W; Fletcher R; Grosveld F Genes Cells; 1996 Jan; 1(1):125-37. PubMed ID: 9078372 [TBL] [Abstract][Full Text] [Related]
12. Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention. Parada LF; Kwon CH; Zhu Y Cold Spring Harb Symp Quant Biol; 2005; 70():173-6. PubMed ID: 16869751 [TBL] [Abstract][Full Text] [Related]
13. Mouse models of neurofibromatosis 1 and 2. Gutmann DH; Giovannini M Neoplasia; 2002; 4(4):279-90. PubMed ID: 12082543 [TBL] [Abstract][Full Text] [Related]
14. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice. Demestre M; Messerli SM; Celli N; Shahhossini M; Kluwe L; Mautner V; Maruta H Phytother Res; 2009 Feb; 23(2):226-30. PubMed ID: 18726924 [TBL] [Abstract][Full Text] [Related]
15. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. Su W; Xing R; Guha A; Gutmann DH; Sherman LS Glia; 2007 May; 55(7):723-33. PubMed ID: 17348023 [TBL] [Abstract][Full Text] [Related]
16. A mild mutator phenotype arises in a mouse model for malignancies associated with neurofibromatosis type 1. Garza R; Hudson RA; McMahan CA; Walter CA; Vogel KS Mutat Res; 2007 Feb; 615(1-2):98-110. PubMed ID: 17208258 [TBL] [Abstract][Full Text] [Related]
17. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Dasgupta B; Li W; Perry A; Gutmann DH Cancer Res; 2005 Jan; 65(1):236-45. PubMed ID: 15665300 [TBL] [Abstract][Full Text] [Related]
18. Tumour suppressor genes, immunology and local manifestations of neurofibromatosis phenotypes. Gerosa PL; Spinelli M; Iannarelli S; Giussani G; Canepari C; Fontana A; Vai C; Bizzozero L Panminerva Med; 1996 Sep; 38(3):157-63. PubMed ID: 9009679 [TBL] [Abstract][Full Text] [Related]
19. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Munchhof AM; Li F; White HA; Mead LE; Krier TR; Fenoglio A; Li X; Yuan J; Yang FC; Ingram DA Hum Mol Genet; 2006 Jun; 15(11):1858-69. PubMed ID: 16648142 [TBL] [Abstract][Full Text] [Related]